MBXBFMBXBFOTC

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

accessnewswire.com

Microbix Presents Reference-Material Innovations at EUROGIN

QUANTDx Samples with "Normalized" Viral Loads for Validating HPV Assays MISSISSAUGA, ON / ACCESS Newswire / March 17, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF)(Microbix® ), a life sciences innovator, manufacturer, and exporter, announces that it is presenting results of novel QUANTDx™ reference materials designed to emulate real-life human papillomavirus ("HPV") patient-samples and thereby better support the validation of molecular (e.g., "PCR") tests for infection.

accessnewswire.com

Microbix's Clot-Buster Drug Project Advances

Drug Substance Manufacturing Methods Modernized MISSISSAUGA, ON / ACCESS Newswire / March 10, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces that the contract development and manufacturing organization ("CDMO") engaged by its funding and commercialization partner, Sequel Pharma, LLC ("Sequel"), has modernized production methods for the active ingredient (i.e., "Drug Substance") of Kinlytic® urokinase ("Kinlytic"), a biologic for dissolving blood clots.

accessnewswire.com

Microbix Announces Issuance of Stock Options

Using Shareholder-Approved Plan to Incentivize and Retain MISSISSAUGA, ON / ACCESS Newswire / February 24, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF) (Microbix®), a life sciences innovator, manufacturer, and exporter, announces the issuance of stock options under its shareholder-approved stock option plan (the "Stock Option Plan"), as part of its compensation programs to incentivize and retain its board of directors, executives, and managers. Details of the Option Issuance In consultation with management, Microbix's Board of Directors has approved the issuance of 2,600,000 options in accordance with the terms of the Stock Option Plan.

seekingalpha.com

Microbix Biosystems Inc. (MBX:CA) Q1 2026 Earnings Call Transcript

accessnewswire.com

Microbix Reports Results for Q1 2026

Q1 Revenues of $4.2 million and Controlled Net Loss MISSISSAUGA, ON / ACCESS Newswire / February 12, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, reports results for its first quarter of fiscal 2026 ended December 31, 2025 ("Q1"). Results for Q1 demonstrated the Company's efforts to rebuild revenues back above its breakeven point following two client setbacks in mid-2025, with revenue growth of 13% compared to Q4 fiscal 2025.

accessnewswire.com

Microbix Welcomes The College of American Pathologists as a Client For Supply of QAPs for PT/EQA Programs

MISSISSAUGA, ON / ACCESS Newswire / February 10, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF) (Microbix®), a life sciences innovator, manufacturer, and exporter, is pleased to welcome the College of America Pathologists ("CAP") as a customer for Microbix quality assessment products ("QAPs™") for use in CAP clinical laboratory proficiency-testing ("PT") programs, also commonly known as External Quality Assessments ("EQA"). The College of American Pathologists is a member-based organization comprising approximately 20,000 board-certified pathologists.

accessnewswire.com

Microbix Schedules Release of Results for Q1 Fiscal 2026

Results Release and Webinar Discussion on Morning of February 12, 2026 MISSISSAUGA, ON / ACCESS Newswire / February 5, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF)(Microbix® ), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its first quarter of fiscal 2026 ended December 31, 2025 ("Q1 2026") prior to the start of trading on February 12, 2026. At 10:00 AM ET that day, Microbix intends to hold a webinar discussion of Q4 2025 results with its CEO, CFO, and COO.

accessnewswire.com

Microbix Presents Molecular Pathology Platform Results

Novel Quality Controls to Enable QC & Inter-Laboratory Standardization MISSISSAUGA, ON / ACCESS Newswire / February 4, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is presenting results of its novel Quality Assessment Products ("QAPs™") and platform technology for supporting the quality management and reproducibility of Molecular Pathology derived diagnoses of infectious diseases at Labquality Days, a lab diagnostics conference taking place in Helsinki, Finland from February 5 to 6, 2026. Molecular Pathology is the branch of medicine that integrates the use of traditional determination of cell types and tissue conformation (Pathology) with the analysis of nucleic acids (DNA or RNA) within those cells and tissues (Molecular Diagnostics).

accessnewswire.com

Microbix Updates Investor Presentation on its Website

In Response to OSC Requirements to Explain EBITDA (a non-IFRS measure) MISSISSAUGA, ON / ACCESS Newswire / January 9, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF) (Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it has updated the investor presentation on its corporate website in response to comments of staff of the Ontario Securities Commission (OSC & OSC Staff) in relation to its usage of earnings before interest, taxes, depreciation, and amortization (EBITDA), a measure of financial results not formally-defined by International Financial Reporting Standards (IFRS). Specifically, over the course of a much broader OSC review of company continuous disclosure materials, it was identified that Microbix referred to EBITDA on two slides within its investor-oriented PowerPoint presentation.

accessnewswire.com

Microbix Commercializes SARS-CoV-2 (COVID) Recombinant Antigen For Usage in QAPs and Test Manufacturing

MISSISSAUGA, ON / ACCESS Newswire / January 7, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF) (Microbix®), a life sciences innovator, manufacturer, and exporter, announces the commercial usage of its first recombinant antigen product, the nucleocapsid protein of the SARS-CoV-2 virus (COVID-19), in its quality assessment products ("QAPs™") and its availability at commercial scale for test manufacturers. This is the first commercial product to emerge from the development program announced in January 2025, whereby Microbix committed to extend its capabilities into recombinant (i.e.

seekingalpha.com

Microbix Biosystems Inc. (MBX:CA) Q4 2025 Earnings Call Transcript

globenewswire.com

Microbix Schedules Release of Results for Q4 Fiscal 2025

Results Release and Webinar Discussion on Morning of December 18, 2025 Results Release and Webinar Discussion on Morning of December 18, 2025

globenewswire.com

Microbix Launches New Products to Support H3N2 Flu Testing

MISSISSAUGA, Ontario, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of QAPs™ quality assessment products and availability of QUANTDx™ reference materials to support antigen or molecular tests for H3N2 strains of seasonal Influenza A (a.k.a., the “Flu”).

globenewswire.com

Microbix & Seegene Mexico Collaborate to Improve Test Accuracy

Making HPV Tests & Quality Assessment Products Available across Mexico Making HPV Tests & Quality Assessment Products Available across Mexico

globenewswire.com

Microbix Presenting at Muskoka Capital Event

MISSISSAUGA, Ontario, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting to investors at the Muskoka Capital Event, organized by Capital Event Management Ltd.

globenewswire.com

Microbix Assisting EMQN with Second Genetic-Test EQA Program

MISSISSAUGA, Ontario and MANCHESTER, United Kingdom, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, and EMQN CIC (EMQN), a global supplier of laboratory external quality assessment (“EQA”) schemes for human genomic testing, announce the go-live of a program to support rapid and accurate identification of patients who carry gene-variants associated with faster and slower than normal metabolism of the widely-prescribed antiplatelet (anti-clotting) drug Clopidogrel (brand named Plavix®).

globenewswire.com

Microbix Client Labquality Introduces Novel EQA Scheme at ESCV

Supporting Clinical Labs in Accurately Identifying HPV-associated Head and Neck Cancers Supporting Clinical Labs in Accurately Identifying HPV-associated Head and Neck Cancers

globenewswire.com

Microbix Hosts Ontario Minister Stephen Crawford

Site Visit & Discussions at Biotech Manufacturing Facilities in Mississauga Site Visit & Discussions at Biotech Manufacturing Facilities in Mississauga

seekingalpha.com

Microbix Biosystems Inc. (MBXBF) Q2 2025 Earnings Call Transcript

Microbix Biosystems Inc. (OTCQX:MBXBF) Q3 2025 Earnings Conference Call August 14, 2025 10:00 AM ET Company Participants Cameron L. Groome - President, CEO & Director James S.

globenewswire.com

Microbix Reports Results for Q3 Fiscal 2025

MISSISSAUGA, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and nine months of fiscal 2025 ended June 30, 2025 (“Q3” and “YTD”). Sales for Q3 were down for both Antigens and QAPs™, while YTD Antigens were up and QAPs were down YTD.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance